Artur Jurczyszyn, MD, PhD, Jagiellonian University Medical College, Kraków, Poland, briefly discusses the importance of bone disease control in multiple myeloma, and highlights agents being used in this setting, including denosumab and zoledronic acid. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.